ACS Biomaterials Science & Engineering,
Journal Year:
2024,
Volume and Issue:
10(8), P. 4701 - 4715
Published: July 3, 2024
The
utilization
of
traditional
therapies
(TTS),
such
as
chemotherapy,
reactive
oxygen
species-based
therapy,
and
thermotherapy,
to
induce
immunogenic
cell
death
(ICD)
in
tumor
cells
has
emerged
a
promising
strategy
for
the
activation
antitumor
immune
response.
However,
limited
effectiveness
most
TTS
inducing
ICD
effect
tumors
hinders
their
applications
combination
with
immunotherapy.
To
address
this
challenge,
various
intelligent
strategies
have
been
proposed
strengthen
these
TTS,
then
achieve
synergistic
efficacy
These
primarily
focus
on
augmenting
or
facilitating
antigen
(released
by
cells)
presentation
process
during
they
are
systematically
summarized
review.
Finally,
existing
bottlenecks
prospects
application
regulation
also
discussed.
Small,
Journal Year:
2025,
Volume and Issue:
21(11)
Published: Feb. 14, 2025
Abstract
Immunotherapy
is
a
promising
new
approach
for
tumor
treatment.
However,
its
clinical
application
hindered
by
insufficient
immunogenicity,
hypoxia,
and
immunosuppressive
microenvironment
(TME).
Here,
oxygen
pump
microneedles
(OPMNs)
loaded
with
zinc‐doped
copper
sulfide
nanoflowers
(ZCS
NFs)
PD‐L1
small
interfering
RNA
(siPD‐L1)
(OPMNs‐ZCS@siPD‐L1)
are
developed
boosting
immunotherapy.
OPMN‐ZCS@siPD‐L1
enhances
immunogenicity
through
ZCS
NFs
inducing
cuproptosis,
reverses
TME
siPD‐L1,
promotes
drug
penetration,
ameliorates
hypoxia
bubbles.
More
importantly,
cuproptosis‐induced
mitochondrial
DNA
(mtDNA)
together
Zn
2+
co‐activate
the
STING
pathway,
triggering
robust
immune
response.
increases
sensitivity
to
cuproptosis
induces
immunogenic
cell
death
(ICD)
in
vivo
vitro,
which
significantly
inhibits
progression
metastasis.
The
novel
strategy
of
“increasing
throttle”
(cuproptopsis‐mediated
activation
&
ICD
effect)
combined
“releasing
brake”
(PD‐L1
inhibition
improvement)
provides
enhancing
percutaneous
ACS Applied Materials & Interfaces,
Journal Year:
2024,
Volume and Issue:
16(11), P. 13481 - 13495
Published: March 8, 2024
Ferroptosis,
as
a
type
of
regulated
cell
death,
can
trigger
the
release
damage-associated
molecular
patterns
from
cancer
cells
and
lead
to
enhancement
immune
recognition.
Fenton
reaction-mediated
chemodynamic
therapy
could
initiate
ferroptosis
by
generating
lipid
peroxides,
but
its
efficiency
would
be
greatly
restricted
insufficient
H2O2
antioxidant
system
within
tumor.
Herein,
this
work
reports
successful
preparation
self-supplied
glutathione
(GSH)-depletion
therapeutic
nanocomposites
(Cu2O@Au)
through
in
situ
growth
Au
nanoparticles
on
surface
cuprous
oxide
(Cu2O)
nanospheres.
Upon
delivery
into
cells,
released
Cu2O
consume
endogenous
H2S
colorectal
form
Cu31S16
nanoparticles,
while
NPs
catalyze
glucose
generate
gluconic
acid.
The
self-supplying
lower
acidity
amplify
Cu
ion-induced
Fenton-like
reaction.
Meanwhile,
consumption
reduce
GSH
generation
disrupting
pentose
phosphate
pathway.
Additionally,
Cu2+/Cu+
catalytic
cycle
promotes
depletion
GSH,
leading
peroxide
accumulation
ferroptosis.
It
was
found
that
onset
triggered
Cu2O@Au
immunologic
promote
dendritic
maturation
T-cell
infiltration,
finally
enhance
antitumor
efficacy
PD-L1
antibody.
In
summary,
collaborative
action
produces
remarkable
effect,
which
provides
promising
treatment
strategy
for
cancer.
Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 1, 2024
Abstract
Immunotherapy
offers
a
promising
avenue
for
reducing
tumor
metastasis
and
recurrence
but
faces
challenges
from
the
immunosuppressive
microenvironment
(TIME)
restricted
antigen
presentation.
To
address
these
challenges,
this
study
have
developed
an
innovative
approach
utilizing
molybdenum
(Mo)‐doped
Prussian
blue
nanoparticles
coated
with
cancer
cell
membrane
(CCM),
referred
to
as
PMo@CCM.
This
novel
nanoplatform
excels
in
performing
photothermal
therapy
(PTT),
while
Mo
Fe
components
effectively
deplete
glutathione
(GSH)
generate
reactive
oxygen
species
(ROS),
thereby
significantly
enhancing
chemodynamic
(CDT)
remodeling
TIME.
The
synergistic
PTT/CDT
not
only
induces
immunogenic
death
(ICD)
also
facilitates
CCM
coating
further
supplies
antigens
prompts
dendritic
(DC)
maturation.
comprehensive
strategy
markedly
enhances
effectiveness
of
immunotherapy,
evidenced
by
significant
increase
T
activation.
Moreover,
use
programmed
protein
1
antibodies
(anti
PD‐1)
blocks
PD‐1
immune
checkpoint
pathway.
RNA
sequencing
analysis
has
identified
genes
associated
observed
substantial
reduction
growth.
In
conclusion,
PMo@CCM
enables
homologously
targeted
therapy,
guided
magnetic
resonance
imaging
(PTI&MRI),
impeding
progression
both
primary
metastatic
tumors.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(29), P. 18801 - 18833
Published: July 9, 2024
Tumor
vaccines,
an
important
part
of
immunotherapy,
prevent
cancer
or
kill
existing
tumor
cells
by
activating
restoring
the
body's
own
immune
system.
Currently,
various
formulations
vaccines
have
been
developed,
including
cell
membrane
DNA
mRNA
polypeptide
virus-vectored
and
tumor-in-situ
vaccines.
There
are
also
multiple
delivery
systems
for
such
as
liposomes,
vesicles,
viruses,
exosomes,
emulsions.
In
addition,
to
decrease
risk
escape
tolerance
that
may
exist
with
a
single
vaccine,
combination
therapy
radiotherapy,
chemotherapy,
checkpoint
inhibitors,
cytokines,
CAR-T
therapy,
photoimmunotherapy
is
effective
strategy.
Given
critical
role
in
here,
we
look
back
history
discuss
antigens,
adjuvants,
formulations,
systems,
mechanisms,
future
directions
